Nautilus Biotechnology (NAUT) Times Interest Earned (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Times Interest Earned of -$0.45 for Q2 2026, up 5.11% sequentially from -$0.48 in Q2 2025, and up 5.11% YoY from -$0.43 in Q2 2025.
Nautilus Biotechnology (NAUT) Times Interest Earned (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Times Interest Earned for 4 years, with the latest figure at -$0.45 in Q2 2026.
- Quarterly Times Interest Earned rose 5.11% year-over-year to -$0.45 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.01 (down 84.55% YoY) and the FY2020 annual result came in at -$0.01, changed N/A from the prior year.
- Times Interest Earned grew to -$0.45 in Q2 2026 per NAUT's latest filing, from -$0.48 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.45 in Q2 2026 and troughed at -$0.48 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.45 |
| Jun 30, 2025 | -0.48 |
| Mar 31, 2021 | -5.93 |
| Dec 31, 2020 | -0.72 |
| Sep 30, 2020 | -0.47 |